Tucatinib, trastuzumab, ramucirumab, and paclitaxel in HER2+ gastroesophageal cancer
What is the Purpose of this Study?
-Take the study drug, tucatinib, by mouth twice a day
-Get trastuzumab, ramucirumab, and paclitaxel through an I.V. once every 1 to 2 weeks
-Give blood and urine samples
-Have regular CT or MRI scans
Who Can Participate in this Study?
Adults with HER2+ cancer and one of the following tumor types:
-Gastric adenocarcinoma (a type of stomach cancer)
-Gastroesophageal junction adenocarcinoma (a type of cancer that occurs where the esophagus meets the stomach)
What is Involved?
We are doing this study to see if the study drug, tucatinib, is safe and effective to use with trastuzumab, ramucirumab, and paclitaxel. We also want to find the best dose of paclitaxel to use when combined with the 3 other drugs.